InVitae Corp (NYSE:NVTA) General Counsel Thomas Brida sold 13,663 shares of InVitae stock in a transaction on Monday, August 19th. The stock was sold at an average price of $25.29, for a total transaction of $345,537.27. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of NYSE:NVTA traded up $0.69 during trading on Wednesday, reaching $26.45. 3,174,525 shares of the company’s stock traded hands, compared to its average volume of 1,863,986. The company has a debt-to-equity ratio of 0.36, a current ratio of 7.18 and a quick ratio of 7.18. InVitae Corp has a 12 month low of $9.04 and a 12 month high of $28.75. The company has a 50 day moving average of $24.83 and a 200-day moving average of $21.71. The stock has a market capitalization of $2.40 billion, a P/E ratio of -13.63 and a beta of 2.53.

InVitae (NYSE:NVTA) last announced its quarterly earnings data on Tuesday, August 6th. The medical research company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.06). InVitae had a negative net margin of 83.69% and a negative return on equity of 58.48%. The business had revenue of $53.48 million for the quarter, compared to the consensus estimate of $50.17 million. During the same period in the prior year, the company earned ($0.47) EPS. InVitae’s quarterly revenue was up 43.3% on a year-over-year basis. Equities research analysts predict that InVitae Corp will post -2.11 earnings per share for the current fiscal year.

Several equities research analysts have recently weighed in on the stock. Chardan Capital reissued a “buy” rating and issued a $30.00 target price on shares of InVitae in a research report on Tuesday, June 11th. Oppenheimer set a $34.00 target price on shares of InVitae and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Zacks Investment Research downgraded shares of InVitae from a “buy” rating to a “hold” rating in a research report on Friday, April 26th. Benchmark reaffirmed a “buy” rating and set a $28.00 price objective (up previously from $26.00) on shares of InVitae in a research report on Wednesday, August 7th. Finally, Leerink Swann set a $31.00 price objective on shares of InVitae and gave the company a “buy” rating in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $28.17.

Several large investors have recently made changes to their positions in the stock. Two Sigma Advisers LP acquired a new stake in shares of InVitae in the 4th quarter worth approximately $226,000. Dimensional Fund Advisors LP acquired a new stake in shares of InVitae in the 4th quarter worth approximately $319,000. Pennsylvania Trust Co acquired a new stake in shares of InVitae in the 1st quarter worth approximately $8,545,000. Bank of Montreal Can lifted its stake in shares of InVitae by 377.9% in the 1st quarter. Bank of Montreal Can now owns 77,810 shares of the medical research company’s stock worth $1,823,000 after acquiring an additional 61,528 shares during the period. Finally, Principal Financial Group Inc. lifted its stake in shares of InVitae by 148.1% in the 4th quarter. Principal Financial Group Inc. now owns 29,612 shares of the medical research company’s stock worth $328,000 after acquiring an additional 17,676 shares during the period. 87.51% of the stock is owned by institutional investors and hedge funds.

InVitae Company Profile

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.

Featured Story: What is a Leveraged Buyout (LBO)?

Insider Buying and Selling by Quarter for InVitae (NYSE:NVTA)

Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.